The method, Magnified Analysis of the Protein (MAP), combines expandable hydrogel-tissue hybrids with antibody labeling to let scientists observe the structure of cell and tissue proteomes.
The company uses multiple-reaction monitoring mass spectrometry to measure exosome-bound proteins that can predict a woman's risk of preterm delivery.
The companies will jointly offer services and equipment solutions for the development, high-volume manufacture, and launch of multiplexed in vitro diagnostics.
Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
The company posted Q2 revenues of $536.6 million, up from $494.7 million in Q2 2015 and beating the average Wall Street estimate of $523.4 million.
In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.
Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.
Olympic athletes this summer will also undergo gene doping testing, according to Wired.
A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.